Who Paid My Doc
Adstiladrin
Biological Oncology
NDC 55566-1050-1
General payments
$2,214,127
Research payments
$2,369,950
Through program year 2025, $2,214,127 in general payments and $2,369,950 in research payments were reported against Adstiladrin (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,398,956 | 11,273 |
| 2025 | Research | $1,944,378 | 238 |
| 2024 | General | $815,172 | 6,892 |
| 2024 | Research | $425,572 | 75 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 72 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 50 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
18,165 general · 313 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.